IbogaineVault / Portal / Outcomes

Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans

Davis, Alan K., Averill, Lynnette A., Sepeda, Nathan D., Barsuglia, Joseph P., Amoroso, Timothy · 2020 · Chronic Stress

Outcomes Observational high

AI-extracted · unverified · confirm at source

Retrospective n=51 SOF Veterans (2017-2019): Ibogaine+5-MeO-DMT showed very large reductions in PTSD (PCL-5, d=3.6), depression (PHQ-2, d=3.7), anxiety (GAD-2, d=3.1), suicidal ideation (d=1.9), cognitive impairment (d=2.8).

Dosing: Ibogaine HCl 10 mg/kg oral; 5-MeO-DMT ~50 mg inhaled (5 + 15 + 30 mg, optional 4th dose 30 mg, possible 5th up to 45 mg) (oral)

Sample size: 51

Contraindications: Current eating disorders, Current or past psychotic spectrum disorders, Bipolar I disorder, Symptoms of impaired reality testing, Contraindicated medications without proper taper, Cardiac abnormalities on ECG screening, Positive urine toxicology or alcohol screen on treatment day, Obesity or age >55 without passing stress test

View primary source ↗View entry in vault ↗